About: Clomiphene and Its Isomers Block Ebola Virus Particle Entry and Infection with Similar Potency: Potential Therapeutic Implications

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Clomiphene and Its Isomers Block Ebola Virus Particle Entry and Infection with Similar Potency: Potential Therapeutic Implications Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Clomiphene and Its Isomers Block Ebola Virus Particle Entry and Infection with Similar Potency: Potential Therapeutic Implications
Creator	Hoenen, Thomas White, Judith Barnes, Alyson Fontenot, Gregory Kuhn, Jens Nelson, Elizabeth Wiehle, Ronald
Source	PMC
abstract	The 2014 outbreak of Ebola virus (EBOV) in Western Africa highlighted the need for anti-EBOV therapeutics. Clomiphene is a U.S. Food and Drug Administration (FDA)-approved drug that blocks EBOV entry and infection in cells and significantly protects EBOV-challenged mice. As provided, clomiphene is, approximately, a 60:40 mixture of two stereoisomers, enclomiphene and zuclomiphene. The pharmacokinetic properties of the two isomers vary, but both accumulate in the eye and male reproductive tract, tissues in which EBOV can persist. Here we compared the ability of clomiphene and its isomers to inhibit EBOV using viral-like particle (VLP) entry and transcription/replication-competent VLP (trVLP) assays. Clomiphene and its isomers inhibited the entry and infection of VLPs and trVLPs with similar potencies. This was demonstrated with VLPs bearing the glycoproteins from three filoviruses (EBOV Mayinga, EBOV Makona, and Marburg virus) and in two cell lines (293T/17 and Vero E6). Visual problems have been noted in EBOV survivors, and viral RNA has been isolated from semen up to nine months post-infection. Since the clomiphene isomers accumulate in these affected tissues, clomiphene or one of its isomers warrants consideration as an anti-EBOV agent, for example, to potentially help ameliorate symptoms in EBOV survivors.
has issue date	2016-08-02(xsd:dateTime)
bibo:doi	10.3390/v8080206
bibo:pmid	27490565
has license	cc-by
sha1sum (hex)	f243e05a2d51029218e0c313b20fa57c65104a62
schema:url	https://doi.org/10.3390/v8080206
resource representing a document's title	Clomiphene and Its Isomers Block Ebola Virus Particle Entry and Infection with Similar Potency: Potential Therapeutic Implications
has PubMed Central identifier	PMC4997570
has PubMed identifier	27490565
schema:publication	Viruses
resource representing a document's body	covid:f243e05a2d51029218e0c313b20fa57c65104a62#body_text
is schema:about of	named entity 'replication' named entity 'selective estrogen receptor modulator' named entity 'clomiphene' named entity 'process' named entity 'approved drug' named entity 'therapeutics' named entity 'inhibitors' named entity 'tissue culture' named entity 'basis' named entity 'membranes' named entity '[32' named entity 'activity' named entity 'host' named entity 'antibodies' named entity 'U.S.' named entity 'EBOV' named entity 'consideration' named entity 'EBOV' named entity 'Ebola virus' named entity 'Particle' named entity 'Infection' named entity 'Block' covid:arg/f243e05a2d51029218e0c313b20fa57c65104a62 named entity 'isolated' named entity 'Drug' named entity 'This' named entity 'accumulate' named entity 'beta' named entity 'isomers' named entity 'pharmacokinetic' named entity 'infection' named entity 'Western Africa' named entity 'late' named entity 'approved drugs' named entity 'drugs' named entity 'complex' named entity 'EBOV' named entity 'EBOV' named entity 'men' named entity 'Clomiphene' named entity 'assays' named entity 'mouse' named entity 'vary' named entity 'combination' named entity 'clomiphene' named entity 'warrants' named entity 'Drug' named entity 'ability' named entity 'cocktail' named entity 'levels' named entity 'estrogen receptor' named entity 'Therapeutic' named entity 'Potential' named entity 'EBOV' named entity 'approved drug' named entity 'EBOV' named entity 'anti-viral drugs' named entity 'male reproductive tract' named entity 'clomiphene' named entity 'low molecular weight' named entity 'stereoisomers' named entity 'clomiphene' named entity 'isomers' named entity 'isomers' named entity 'U.S. Food and Drug Administration' named entity 'transcription' named entity 'EBOV' named entity 'isomers' named entity 'impotence' named entity 'EBOV' named entity 'approved drugs' named entity 'infection' named entity 'clomiphene' named entity 'Visual problems' named entity 'cell cultures'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software